Description_x000D_ General description_x000D_ Peripheral myelin protein 22 (PMP22), also called as growth arrest-specific protein 3 (GAS-3), is a tetraspan glycoprotein, encoded by the gene mapped to human chromosome 17p12–13. PMP22 is highly expressed in myelin-forming Schwann cells of peripheral nerves._x000D_ Immunogen_x000D_ The antiserum was produced against synthesized peptide derived from human PMP22._x000D_ Immunogen Range: 111-160_x000D_ Application_x000D_ Anti-PMP22 antibody produced in rabbit has been used in:_x000D_ • immunofluorescence_x000D_ • western blotting_x000D_ • immunohistochemistry_x000D_ Anti-PMP22, C-Terminal antibody produced in rabbit has been used in immunofluorescence analysis._x000D_ Physical form_x000D_ Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Peripheral myelin protein 22 (PMP22) plays a vital role in myelination during development of peripheral nerve, cell–cell interactions, cell proliferation, maintenance of axons and the determination of myelin thickness and stability. Biological function of PMP22, might include formation and or maintenance of intercellular junctions and possibly of tight junctions (TJs). Aberrations, duplications or mutations in PMP22 gene lead to majority of heritable demyelinating peripheral neuropathies, such as Charcot-Marie-tooth disease type IA (CMT1A) and Dejerine-Sottas syndrome. PMP2, might be involved in regulation of Schwann cell proliferation and differentiation.5 Overexpression of PMP22 might contribute to the development of chronic myeloid leukemia (CML). PMP22 might, thus, act as a therapeutic target for the treatment of CML._x000D_ Features and Benefits_x000D_ Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.